Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2022 Filed Feb 26, 2022 02:25 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 518 | $35.39 | $18,332.02 |
DisclosureSEC source: 0001722482-22-000057 · wf-form4_164584229480236.xml · nonDerivative · entry 2 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,320 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 02:22 UTC |
Henson MeghanEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 931 | $35.39 | $32,948.09 |
DisclosureSEC source: 0001722482-22-000055 · wf-form4_164584209680334.xml · nonDerivative · entry 2 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,405 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 02:19 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
Tax withholdingCommon Stock | 1,137 | $35.39 | $40,238.43 |
DisclosureSEC source: 0001722482-22-000053 · wf-form4_164584193773455.xml · nonDerivative · entry 2 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,448 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 02:16 UTC |
Miller JustinEVP & General Counsel
|
Tax withholdingCommon Stock | 583 | $35.39 | $20,632.37 |
DisclosureSEC source: 0001722482-22-000051 · wf-form4_164584172618832.xml · nonDerivative · entry 2 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,247 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 02:11 UTC |
Stubblefield MichaelDirector · CEO
|
Tax withholdingCommon Stock | 7,866 | $35.39 | $278,377.74 |
DisclosureSEC source: 0001722482-22-000049 · wf-form4_164584147865249.xml · nonDerivative · entry 2 Stubblefield Michael · CIK 0001776153 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,041 F2 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSU's. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:27 UTC |
Couturier ChristopheEVP, AMEA
|
GrantStock Options (Right to Buy) · Derivative | 17,483 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000059 · wf-form4_164584246004889.xml · derivative · entry 3 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,483 Underlying: Common Stock · 17,483 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:27 UTC |
Couturier ChristopheEVP, AMEA
|
GrantCommon Stock | 6,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000059 · wf-form4_164584246004889.xml · nonDerivative · entry 1 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,595 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:34 UTC |
Szlosek Thomas AEVP & CFO
|
GrantStock Options (Right to Buy) · Derivative | 48,079 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000063 · wf-form4_164584285096084.xml · derivative · entry 3 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,079 Underlying: Common Stock · 48,079 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:34 UTC |
Szlosek Thomas AEVP & CFO
|
GrantCommon Stock | 16,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000063 · wf-form4_164584285096084.xml · nonDerivative · entry 1 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,789 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:36 UTC |
Vanderhaegen FredericEVP, Americas & Europe
|
GrantStock Options (Right to Buy) · Derivative | 43,708 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000065 · wf-form4_164584298246263.xml · derivative · entry 3 Vanderhaegen Frederic · CIK 0001776162 · EVP, Americas & Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,708 Underlying: Common Stock · 43,708 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:36 UTC |
Vanderhaegen FredericEVP, Americas & Europe
|
GrantCommon Stock | 15,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000065 · wf-form4_164584298246263.xml · nonDerivative · entry 1 Vanderhaegen Frederic · CIK 0001776162 · EVP, Americas & Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,190 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC |
Brophy GerardEVP, Biopharma Production
|
GrantStock Options (Right to Buy) · Derivative | 43,708 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · derivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,708 Underlying: Common Stock · 43,708 shares Expires 2032-02-23 F5 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC |
Brophy GerardEVP, Biopharma Production
|
GrantCommon Stock | 15,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,291 F3 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:32 UTC |
Brophy GerardEVP, Biopharma Production
|
SaleCommon Stock | 3,059 | $33.79 | $103,363.61 |
DisclosureSEC source: 0001722482-22-000061 · wf-form4_164584265312525.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,181 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.75 to $33.94 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:25 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
GrantStock Options (Right to Buy) · Derivative | 14,858 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000057 · wf-form4_164584229480236.xml · derivative · entry 3 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,858 Underlying: Common Stock · 14,858 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:25 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
GrantCommon Stock | 5,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000057 · wf-form4_164584229480236.xml · nonDerivative · entry 1 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,838 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:22 UTC |
Henson MeghanEVP, Chief HR Officer
|
GrantStock Options (Right to Buy) · Derivative | 24,035 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000055 · wf-form4_164584209680334.xml · derivative · entry 3 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,035 Underlying: Common Stock · 24,035 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:22 UTC |
Henson MeghanEVP, Chief HR Officer
|
GrantCommon Stock | 8,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000055 · wf-form4_164584209680334.xml · nonDerivative · entry 1 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,336 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:19 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
GrantStock Options (Right to Buy) · Derivative | 28,406 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000053 · wf-form4_164584193773455.xml · derivative · entry 3 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,406 Underlying: Common Stock · 28,406 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:19 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
GrantCommon Stock | 9,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000053 · wf-form4_164584193773455.xml · nonDerivative · entry 1 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,585 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:16 UTC |
Miller JustinEVP & General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 19,664 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000051 · wf-form4_164584172618832.xml · derivative · entry 3 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,664 Underlying: Common Stock · 19,664 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:16 UTC |
Miller JustinEVP & General Counsel
|
GrantCommon Stock | 6,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000051 · wf-form4_164584172618832.xml · nonDerivative · entry 1 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,830 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:11 UTC |
Stubblefield MichaelDirector · CEO
|
GrantStock Options (Right to Buy) · Derivative | 202,143 | $0.00 Strike: $33.09 | $0.00 |
DisclosureSEC source: 0001722482-22-000049 · wf-form4_164584147865249.xml · derivative · entry 3 Stubblefield Michael · CIK 0001776153 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,143 Underlying: Common Stock · 202,143 shares Expires 2032-02-23 F3 · derivative.exercise_date: Reflects a grant of stock options that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:11 UTC |
Stubblefield MichaelDirector · CEO
|
GrantCommon Stock | 69,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000049 · wf-form4_164584147865249.xml · nonDerivative · entry 1 Stubblefield Michael · CIK 0001776153 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,320,907 F1 · kind: Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 23, 2023. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 17:28 UTC |
Couturier ChristopheEVP, AMEA
|
Tax withholdingCommon Stock | 1,267 | $34.00 | $43,078.00 |
DisclosureSEC source: 0001722482-22-000045 · wf-form4_164556888738821.xml · nonDerivative · entry 1 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,551 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 321 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:29 UTC |
Szlosek Thomas AEVP & CFO
|
Tax withholdingCommon Stock | 4,040 | $34.00 | $137,360.00 |
DisclosureSEC source: 0001722482-22-000046 · wf-form4_164556892068159.xml · nonDerivative · entry 1 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,168 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:29 UTC |
Miller JustinEVP & General Counsel
|
Tax withholdingCommon Stock | 1,328 | $34.00 | $45,152.00 |
DisclosureSEC source: 0001722482-22-000047 · wf-form4_164556895970747.xml · nonDerivative · entry 1 Miller Justin · CIK 0001776122 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,030 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 822 shares acquired under the Avantor Employee Stock Purchase Plan. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:27 UTC |
Brophy GerardEVP, Biopharma Production
|
Tax withholdingCommon Stock | 3,072 | $34.00 | $104,448.00 |
DisclosureSEC source: 0001722482-22-000044 · wf-form4_164556883314906.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,240 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:27 UTC |
Stubblefield MichaelDirector · President and CEO
|
Tax withholdingCommon Stock | 10,959 | $34.00 | $372,606.00 |
DisclosureSEC source: 0001722482-22-000043 · wf-form4_164556880935178.xml · nonDerivative · entry 1 Stubblefield Michael · CIK 0001776153 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,251,022 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:26 UTC |
Vanderhaegen FredericEVP, Europe
|
Tax withholdingCommon Stock | 398 | $28.69 | $11,418.62 |
DisclosureSEC source: 0001722482-22-000042 · wf-form4_164556877280194.xml · nonDerivative · entry 1 Vanderhaegen Frederic · CIK 0001776162 · EVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,080 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 20, 2022 Filed Feb 22, 2022 22:26 UTC |
Eck Steven WSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 448 | $34.00 | $15,232.00 |
DisclosureSEC source: 0001722482-22-000041 · wf-form4_164556875511494.xml · nonDerivative · entry 1 Eck Steven W · CIK 0001748813 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 22:12 UTC |
Murray Mark ChristopherEVP, Biomaterials & AT
|
Tax withholdingCommon Stock | 918 | $37.50 | $34,425.00 |
DisclosureSEC source: 0001722482-22-000014 · wf-form4_164254396077854.xml · nonDerivative · entry 1 Murray Mark Christopher · CIK 0001800013 · EVP, Biomaterials & AT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,680 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 21:59 UTC |
Brophy GerardEVP, Biopharma Production
|
SaleCommon Stock | 11,551 | $38.65 | $446,446.15 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 4 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,312 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.44 to $38.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC |
Brophy GerardEVP, Biopharma Production
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 59,418 | $0.00 Strike: $18.45 | $0.00 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · derivative · entry 5 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,417 Underlying: Common Stock · 59,418 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC |
Brophy GerardEVP, Biopharma Production
|
SaleCommon Stock | 59,418 | $40.77 | $2,422,471.86 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 3 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,863 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.27 to $41.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:59 UTC |
Brophy GerardEVP, Biopharma Production
|
Exercise / conversionCommon Stock | 59,418 | $18.45 | $1,096,262.10 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 2 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 21:58 UTC |
Szlosek Thomas AEVP & CFO
|
Tax withholdingCommon Stock | 8,101 | $42.14 | $341,376.14 |
DisclosureSEC source: 0001722482-22-000010 · wf-form4_164141989427155.xml · nonDerivative · entry 1 Szlosek Thomas A · CIK 0001293167 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,208 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 915 shares acquired under the Avantor Employee Stock Purchase Plan Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 21:59 UTC |
Wondrasch MichaelEVP & CIO
|
Tax withholdingCommon Stock | 9,517 | $42.14 | $401,046.38 |
DisclosureSEC source: 0001722482-22-000012 · wf-form4_164141996982613.xml · nonDerivative · entry 1 Wondrasch Michael · CIK 0001776065 · EVP & CIO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,312 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. F2 · balance_after: Includes 534 shares acquired under the Avantor Employee Stock Purchase Plan Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 21:58 UTC |
Vanderhaegen FredericEVP, Europe
|
Tax withholdingCommon Stock | 1,017 | $42.14 | $42,856.38 |
DisclosureSEC source: 0001722482-22-000009 · wf-form4_164141987168355.xml · nonDerivative · entry 1 Vanderhaegen Frederic · CIK 0001776162 · EVP, Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,478 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| January 02, 2022 Filed Jan 5, 2022 21:59 UTC |
Brophy GerardEVP, Biopharma Production
|
Tax withholdingCommon Stock | 6,516 | $42.14 | $274,584.24 |
DisclosureSEC source: 0001722482-22-000011 · wf-form4_164141993911167.xml · nonDerivative · entry 1 Brophy Gerard · CIK 0001776107 · EVP, Biopharma Production 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,863 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:24 UTC |
Henson MeghanEVP, Chief HR Officer
|
Tax withholdingCommon Stock | 1,877 | $42.14 | $79,096.78 |
DisclosureSEC source: 0001722482-22-000004 · wf-form4_164124503477255.xml · nonDerivative · entry 1 Henson Meghan · CIK 0001839411 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,025 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:21 UTC |
Lewis SheriEVP, Global Ops & Supply Chain
|
Tax withholdingCommon Stock | 4,093 | $42.14 | $172,479.02 |
DisclosureSEC source: 0001722482-22-000002 · wf-form4_164124488710584.xml · nonDerivative · entry 1 Lewis Sheri · CIK 0001839410 · EVP, Global Ops & Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,763 F1 · kind: Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:56 UTC |
Couturier ChristopheEVP, AMEA
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,184 | $0.00 Strike: $23.21 | $0.00 |
DisclosureSEC source: 0001722482-21-000278 · wf-form4_164072856881142.xml · derivative · entry 3 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,901 Underlying: Common Stock · 10,184 shares Expires 2028-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an initial grant of 135,210 of stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on August 22, 2019. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:56 UTC |
Couturier ChristopheEVP, AMEA
|
SaleCommon Stock | 10,184 | $41.63 | $423,959.92 |
DisclosureSEC source: 0001722482-21-000278 · wf-form4_164072856881142.xml · nonDerivative · entry 2 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,497 F1 · kind: Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person herein. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $41.50 to $41.69, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 16:56 UTC |
Couturier ChristopheEVP, AMEA
|
Exercise / conversionCommon Stock | 10,184 | $23.21 | $236,370.64 |
DisclosureSEC source: 0001722482-21-000278 · wf-form4_164072856881142.xml · nonDerivative · entry 1 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:28 UTC |
Couturier ChristopheEVP, AMEA
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 28,125 | $0.00 Strike: $23.21 | $0.00 |
DisclosureSEC source: 0001722482-21-000276 · wf-form4_164029490481631.xml · derivative · entry 6 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,085 Underlying: Common Stock · 28,125 shares Expires 2028-08-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Reflects an initial grant of 135,210 of stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on August 22, 2019. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:28 UTC |
Couturier ChristopheEVP, AMEA
|
SaleCommon Stock | 28,125 | $41.53 | $1,168,031.25 |
DisclosureSEC source: 0001722482-21-000276 · wf-form4_164029490481631.xml · nonDerivative · entry 4 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,497 F1 · kind: Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person herein. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $41.50 to $41.63, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:28 UTC |
Couturier ChristopheEVP, AMEA
|
Exercise / conversionCommon Stock | 28,125 | $23.21 | $652,781.25 |
DisclosureSEC source: 0001722482-21-000276 · wf-form4_164029490481631.xml · nonDerivative · entry 3 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:28 UTC |
Couturier ChristopheEVP, AMEA
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 38,309 | $0.00 Strike: $23.21 | $0.00 |
DisclosureSEC source: 0001722482-21-000276 · wf-form4_164029490481631.xml · derivative · entry 5 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,901 Underlying: Common Stock · 38,309 shares Expires 2028-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Reflects an initial grant of 135,210 of stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on March 9, 2019. Read SEC document |
| December 21, 2021 Filed Dec 23, 2021 16:28 UTC |
Couturier ChristopheEVP, AMEA
|
SaleCommon Stock | 38,309 | $41.00 | $1,570,669.00 |
DisclosureSEC source: 0001722482-21-000276 · wf-form4_164029490481631.xml · nonDerivative · entry 2 Couturier Christophe · CIK 0001684076 · EVP, AMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,497 F1 · kind: Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person herein. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $41.005 to $41.007, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.